Brought to you by 
Series A round by Biohaven brings in $80mm for CNS pipeline development; later adds $20mm
24 Apr 2017
Executive Summary
Biohaven Pharmaceuticals Holding Co. Ltd. (orphan neurologic disease candidates) raised $80mm in a Series A preferred round led by Venrock, which was joined by RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Litmore Capital, and board members John W. Childs and Greg Bailey, MD (who is also the company’s SVP, business development). Cowen & Co. and William Blair were co-placement agents. Prior to this round, the company brought in about $20mm in financing.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A round by Biohaven brings in $80mm for CNS pipeline development; later adds $20mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice